Roivant Sciences

Closed (deSPAC)

Biopharmaceutical company developing and commercializing innovative medicines through its subsidiary Vants

What it is: A private company in biopharmaceutical company developing and commercializing innovative medicines through its subsidiary vants preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now: Merging with Montes Archimedes Acquisition Corp (MAAC) — closed (despac), announced Aug 10, 2021.
What you should know: Data is still being assembled for this company — what is shown below is everything we have verified so far.

Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

The deal it’s entering

Roivant Sciences is merging with Montes Archimedes Acquisition Corp (MAAC) currently marked Closed (deSPAC).

Headline equity value	—
Post-close ticker	ROIV

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Roivant Sciences going public?

Roivant Sciences has an approved merger with the SPAC Montes Archimedes Acquisition Corp (MAAC), announced Aug 10, 2021. The combined company expects to trade as ROIV. Deal status: Closed (deSPAC).

Does Roivant Sciences have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.